Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Background: AntiCD19 CAR-T cells are effective against chemorefractory B cell lymphoma. Patients (pts) with rapidly progressive disease and urgent need for therapy have very poor prognosis and may not be able to receive CAR-T cells in time. Decreasing the apheresis to infusion time can make CAR-T ce...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.3833-3833
Hauptverfasser:	Caimi, Paolo F., Ghobadi, Armin, Reese, Jane, Tomlinson, Benjamin, Otegbeye, Folashade, Ritchey, Julie K, Trummer, Tabatha, Schiavone, Jennifer, Zamborsky, Kayla, Eissenberg, Linda G, Hollaway, Julia, Schneider, Dina, Bakalarz, Kristen, Boughan, Kirsten M, Metheny, Leland, Patel, Seema, Galloway, Erin, Gallogly, Molly, Krueger, Winfried, Kadan, Michael, Pacheco Sanchez, Gabriela, Sharma, Ashish, Wald, David, Cooper, Brenda W., DiPersio, John F., Sekaly, Rafick, Orentas, Rimas J, Dropulic, Boro, de Lima, Marcos J.G.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!